Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Litigation Or Legislation: States Have Dual Path For Pharma Regulation

Executive Summary

States make decisions about whether to use legislation or litigation to address questionable behavior by pharmaceutical companies based on the required scope and speed of the remedial activity, Vermont Assistant Attorney General Julie Brill said

You may also be interested in...

Off-Label Communication Has Risks Beyond Prosecution, Sheehan Says

Pharmaceutical companies should beware of pitfalls of communicating about off-label uses even when such activities can be defended as free speech, Philadelphia Associate U.S. Attorney Jim Sheehan suggested

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts